Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06652100Active Not Recruiting

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Role: lead

NCT04008810Completed

Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease

Role: collaborator

NCT03527160Completed

Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications

Role: collaborator

NCT03057457Unknown

The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population

Role: lead

NCT02121470Completed

NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care

Role: lead

All 5 trials loaded